These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25432075)

  • 1. GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis.
    Srivastava RK; Kaylani SZ; Edrees N; Li C; Talwelkar SS; Xu J; Palle K; Pressey JG; Athar M
    Oncotarget; 2014 Dec; 5(23):12151-65. PubMed ID: 25432075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
    Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
    Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of SHH/GLI1 axis on EMT mediated migration and invasion of breast cancer cells.
    Riaz SK; Ke Y; Wang F; Kayani MA; Malik MFA
    Sci Rep; 2019 Apr; 9(1):6620. PubMed ID: 31036836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GANT-61 Induces Autophagy and Apoptosis in Glioblastoma Cells despite their heterogeneity.
    Carballo GB; Ribeiro JH; Lopes GPF; Ferrer VP; Dezonne RS; Pereira CM; Spohr TCLSE
    Cell Mol Neurobiol; 2021 Aug; 41(6):1227-1244. PubMed ID: 32504326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congenital embryonal rhabdomyosarcoma caused by heterozygous concomitant PTCH1 and PTCH2 germline mutations.
    Taeubner J; Brozou T; Qin N; Bartl J; Ginzel S; Schaper J; Felsberg J; Fulda S; Vokuhl C; Borkhardt A; Kuhlen M
    Eur J Hum Genet; 2018 Jan; 26(1):137-142. PubMed ID: 29230040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumour effects of SFX-01 molecule in combination with ionizing radiation in preclinical and in vivo models of rhabdomyosarcoma.
    Camero S; Milazzo L; Vulcano F; Ceccarelli F; Pontecorvi P; Pedini F; Rossetti A; Scialis ES; Gerini G; Cece F; Pomella S; Cassandri M; Porrazzo A; Romano E; Festuccia C; Gravina GL; Ceccarelli S; Rota R; Lotti LV; Midulla F; Angeloni A; Marchese C; Marampon F; Megiorni F
    BMC Cancer; 2024 Jul; 24(1):814. PubMed ID: 38977944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel small molecule DMAMCL induces differentiation in rhabdomyosarcoma by downregulating of DLL1.
    Li Q; Chen Y; Chen Y; Hua Z; Gong B; Liu Z; Thiele CJ; Li Z
    Biomed Pharmacother; 2024 May; 174():116562. PubMed ID: 38626518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses.
    Stewart E; McEvoy J; Wang H; Chen X; Honnell V; Ocarz M; Gordon B; Dapper J; Blankenship K; Yang Y; Li Y; Shaw TI; Cho JH; Wang X; Xu B; Gupta P; Fan Y; Liu Y; Rusch M; Griffiths L; Jeon J; Freeman BB; Clay MR; Pappo A; Easton J; Shurtleff S; Shelat A; Zhou X; Boggs K; Mulder H; Yergeau D; Bahrami A; Mardis ER; Wilson RK; Zhang J; Peng J; Downing JR; Dyer MA;
    Cancer Cell; 2018 Sep; 34(3):411-426.e19. PubMed ID: 30146332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The palladacycle complex AJ-5 induces apoptotic cell death while reducing autophagic flux in rhabdomyosarcoma cells.
    Bleloch JS; du Toit A; Gibhard L; Kimani S; Ballim RD; Lee M; Blanckenberg A; Mapolie S; Wiesner L; Loos B; Prince S
    Cell Death Discov; 2019; 5():60. PubMed ID: 30701092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of two Fluorescent Complexes and Their use as Multifunctional Nanomedicine Carriers for Rhabdomyosarcoma Treatment.
    Yang P; Xie P; Lin F; Wang T; Zhang L; Yan F
    J Fluoresc; 2024 Jul; ():. PubMed ID: 38985396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors.
    Infante P; Mori M; Alfonsi R; Ghirga F; Aiello F; Toscano S; Ingallina C; Siler M; Cucchi D; Po A; Miele E; D'Amico D; Canettieri G; De Smaele E; Ferretti E; Screpanti I; Uccello Barretta G; Botta M; Botta B; Gulino A; Di Marcotullio L
    EMBO J; 2015 Jan; 34(2):200-17. PubMed ID: 25476449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened.
    Gonnissen A; Isebaert S; Haustermans K
    Oncotarget; 2015 Jun; 6(16):13899-913. PubMed ID: 26053182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.
    Graab U; Hahn H; Fulda S
    Oncotarget; 2015 Apr; 6(11):8722-35. PubMed ID: 25749378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sonic hedgehog-Gli1 signals promote epithelial-mesenchymal transition in ovarian cancer by mediating PI3K/AKT pathway.
    Ke Z; Caiping S; Qing Z; Xiaojing W
    Med Oncol; 2015 Jan; 32(1):368. PubMed ID: 25432698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts.
    Kebenko M; Drenckhan A; Gros SJ; Jücker M; Grabinski N; Ewald F; Grottke A; Schultze A; Izbicki JR; Bokemeyer C; Wellbrock J; Fiedler W
    Cell Signal; 2015 Feb; 27(2):373-81. PubMed ID: 25435423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects.
    Wellbrock J; Latuske E; Köhler J; Wagner K; Stamm H; Vettorazzi E; Vohwinkel G; Klokow M; Uibeleisen R; Ehm P; Riecken K; Loges S; Thol F; Schubert C; Amling M; Jücker M; Bokemeyer C; Heuser M; Krauter J; Fiedler W
    Clin Cancer Res; 2015 May; 21(10):2388-98. PubMed ID: 25745035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Druggable glycolytic requirement for Hedgehog-dependent neuronal and medulloblastoma growth.
    Di Magno L; Manzi D; D'Amico D; Coni S; Macone A; Infante P; Di Marcotullio L; De Smaele E; Ferretti E; Screpanti I; Agostinelli E; Gulino A; Canettieri G
    Cell Cycle; 2014; 13(21):3404-13. PubMed ID: 25485584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondria-derived reactive oxygen species drive GANT61-induced mesothelioma cell apoptosis.
    Lim CB; Prêle CM; Baltic S; Arthur PG; Creaney J; Watkins DN; Thompson PJ; Mutsaers SE
    Oncotarget; 2015 Jan; 6(3):1519-30. PubMed ID: 25544756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcomas.
    HaDuong JH; Martin AA; Skapek SX; Mascarenhas L
    Pediatr Clin North Am; 2015 Feb; 62(1):179-200. PubMed ID: 25435119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase 6 represents a novel drug target in the oncogenic Hedgehog signaling pathway.
    Dhanyamraju PK; Holz PS; Finkernagel F; Fendrich V; Lauth M
    Mol Cancer Ther; 2015 Mar; 14(3):727-39. PubMed ID: 25552369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.